Incyte: BofA Global Research raises price objective to $136 from $124

On July 15, 2026, BofA Global Research announced an upward revision of its price objective for Incyte (INCY), increasing it to $136 from the previous $124. This adjustment reflects the firm’s updated assessment of the company’s financial outlook and market positioning. The revised target suggests a positive outlook on Incyte’s potential performance, based on current market conditions and the firm’s analysis of the company’s strategic direction.

The move follows a comprehensive review of Incyte’s recent business developments and financial performance. BofA Global Research emphasized that the price objective adjustment is grounded in a detailed evaluation of the company’s operations and market dynamics. Investors are advised to consider this update in the context of broader market trends and their own investment strategies.

This change in price objective does not imply a shift in the firm’s overall rating for Incyte. The firm maintains its current stance, with the updated target intended to provide a more accurate reflection of the company’s valuation potential. Investors should consult additional sources and conduct their own due diligence before making investment decisions [1].